- Proceeding Paper
Angiogenesis is the fundamental hallmark of cancers that promotes tumour growth and metastasis through the activation of the TLR4/MD2 receptors. The binding of the bacterial endotoxin known as LPS on the TLR4/MD2 receptors initiates downstream signalling leading to production of pro-angiogenic factors such as VEGF. Therefore, inhibition of the TLR4/MD2 signalling represents a promising strategy to suppress tumour angiogenesis. The new diarylpentanoid analogues N6 and N8 prevent angiogenesis by blocking LPS-induced TLR4 activation in breast cancer cells. The drug likeness and ADMET profiling were evaluated using an insilico method. Autodocking and IMODs server was analysed to determine the binding affinity and stability with the TLR4/MD2 receptor. AlphaFold 3 was analysed to determine the confidence interaction with the TLR4/MD2 receptor. Both compounds exhibit strong binding affinity towards the TLR4-MD2 receptors with binding scores of −8 kcal/mol and −9.7 kcal/mol. However, N6 shows more favourable drug likeness and ADMET profile properties and demonstrates greater structural flexibility, stability and higher confidence interactions compare to N8. These observations suggest that N6 serves as an anti-angiogenic therap that targets TLR4/MD2 receptors.
6 November 2026





